Data protection Impressum

Personalized Medicine

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (April 2024)

30 April 2024

The FIF has once again highlighted its commitment to propelling tech innovation in Geneva by awarding significant financial support to three promising projects.

Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support

29 April 2024

Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding to advance its revolutionary diagnostic technologies.

Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding

22 April 2024

This initiative reflects a broader shift towards life sciences, driven by innovation and a commitment to health, wellness, and sustainability.

The HES-SO strengthens life sciences education and research in the canton of Valais

22 April 2024

Vaud-based biopharma Oculis has secured USD 59 million to extend operations into 2026, following a successful listing on NASDAQ Iceland Main Market.

Oculis announces completion of oversubscribed USD 59 million registered direct offering

15 April 2024

Swibrace, in partnership with the Inselspital in Bern, moves its customized wrist braces into clinical phase, enhancing fracture treatment through 3D printing.

Swibrace advances to clinical phase with innovative 3D-printed wrist braces

15 April 2024

With CHF 7.75 million from the BRH Foundation, the University of Bern and Insel Gruppe have launched a professorship to innovate in rehabilitation.

University of Bern introduces endowed professorship in interdisciplinary rehabilitation

15 April 2024

Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug development.

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment

9 April 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2024)

26 March 2024

This funding is poised to extend the company's financial runway into mid-2025, as it gears up for the approval and launch of pioneering products designed to enhance the lives of individuals with spinal cord injuries (SCI).

ONWARD Medical secures EUR 20 million to expand its spinal cord injury therapies

26 March 2024

1 2 3 4 5 6 7 8 9 … 17